Sheron, Vethanayagam Antony
Shanmugathas, Shivany
Gooden, Tiffany E.
Guruparan, Mahesan
Kumarendran, Balachandran
Lip, Gregory Y. H.
Manaseki-Holland, Semira
Nirantharakumar, Krishnarajah
Shribavan, Kaneshamoorthy
Subaschandren, Kumaran
Haniffa, Rashan
Surenthirakumaran, Rajendra
Thomas, G. Neil
Uruthirakumar, Powsiga
Greenfield, Sheila
Lane, Deirdre A.
Beane, Abi
Sheron, Vethanayagam Antony
Shanmugathas, Shivany
Gooden, Tiffany E.
Guruparan, Mahesan
Kumarendran, Balachandran
Lip, Gregory Y. H.
Manaseki-Holland, Semira
Nirantharakumar, Krishnarajah
Shribavan, Kaneshamoorthy
Subaschandren, Kumaran
Haniffa, Rashan
Surenthirakumaran, Rajendra
Thomas, G. Neil
Uruthirakumar, Powsiga
Greenfield, Sheila
Lane, Deirdre A.
Beane, Abi
Arasalingam, Ajini
Bensenor, Isabela M.
Brocklehurst, Peter
Cheng, Kar Keung
El-Bouri, Wahbi
Feng, Mei
Goulart, Alessandra C.
Guo, Yutao
Gusso, Gustavo
Humphreys, Lindsey
Jolly, Kate
Jowett, Sue
Kodippily, Chamira
Lancashire, Emma
Li, Xuewen
Li, Yan-guang
Lobban, Trudie
Lotufo, Paulo A.
Moore, David
Olmos, Rodrigo D.
Paschoal, Elisabete
Pirasanth, Paskaran
Powsiga, Uruthirakumar
Romagnolli, Carla
Santos, Itamar S.
Shantsila, Alena
Szmigin, Isabelle
Tai, Meihui
Toippa, Timo
Varella, Ana C.
Wang, Hao
Wang, Jingya
Zhang, Hui
Zhong, Jiaoyue
,
Funding for this research was provided by:
National Institute for Health Research (17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management, 17/63/121, NIHR Global Health Research Group on Atrial Fibrillation Management)
Article History
Received: 8 April 2022
Accepted: 22 July 2022
First Online: 23 August 2022
Declarations
:
: Ethical approval was received by the Ethics Review Committee of the Faculty of Medicine at the University of Jaffna (approval number J/ERC/19/107/NDR/0218). All participants provided written informed consent. Patients were not involved in the design or development of this study. All methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: GYHL: Consultant and speaker for BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.DAL: Investigator-initiated educational grants from Bristol-Myers Squibb (BMS), speaker for Bayer, Boehringer Ingeheim, and BMS/Pfizer; Consultant for BMS, and Boehringer Ingelheim.Other authors: Declare no conflict of interest.